Skip to main content

Fresenius says Akorn deal closure could take until next year

FRANKFURT, Nov 22 (Reuters) - German healthcare group Fresenius SE said the planned takeover of Akorn , a U.S. maker of liquid generic drugs, might not be completed before next year as the U.S. antitrust review could take longer than expected.
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.